Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

The use of randomisation-based efficacy estimators in non-inferiority trials.

Gillespie D, Farewell D, Barrett-Lee P, Casbard A, Hawthorne AB, Hurt C, Murray N, Probert C, Stenson R, Hood K.

Trials. 2017 Mar 9;18(1):117. doi: 10.1186/s13063-017-1837-3.

2.

Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance.

Bellerby R, Smith C, Kyme S, Gee J, Günthert U, Green A, Rakha E, Barrett-Lee P, Hiscox S.

Front Oncol. 2016 Jun 20;6:145. doi: 10.3389/fonc.2016.00145. eCollection 2016.

3.

3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.

Gangadhara S, Smith C, Barrett-Lee P, Hiscox S.

BMC Cancer. 2016 Jun 1;16:345. doi: 10.1186/s12885-016-2377-z.

4.

Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.

Jamal-Hanjani M, A'Hern R, Birkbak NJ, Gorman P, Grönroos E, Ngang S, Nicola P, Rahman L, Thanopoulou E, Kelly G, Ellis P, Barrett-Lee P, Johnston SR, Bliss J, Roylance R, Swanton C.

Ann Oncol. 2015 Jul;26(7):1340-6. doi: 10.1093/annonc/mdv178. Epub 2015 May 23.

PMID:
26003169
5.

Radiotherapy for skin cancer: as good as surgery?

Barrett-Lee P.

Br J Dermatol. 2014 Nov;171(5):930. doi: 10.1111/bjd.13393. No abstract available.

PMID:
25409992
6.

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).

Hall E, Cameron D, Waters R, Barrett-Lee P, Ellis P, Russell S, Bliss JM, Hopwood P; TACT Trial Investigators..

Eur J Cancer. 2014 Sep;50(14):2375-89. doi: 10.1016/j.ejca.2014.06.007. Epub 2014 Jul 24.

7.

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H; AZURE investigators..

Lancet Oncol. 2014 Aug;15(9):997-1006. doi: 10.1016/S1470-2045(14)70302-X. Epub 2014 Jul 15.

PMID:
25035292
8.

Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.

Borley A, Mercer T, Morgan M, Dutton P, Barrett-Lee P, Brunelli M, Jasani B.

Br J Cancer. 2014 Apr 15;110(8):2139-43. doi: 10.1038/bjc.2014.147. Epub 2014 Apr 1.

9.

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A.

Breast Cancer Res Treat. 2014 Apr;144(2):331-41. doi: 10.1007/s10549-014-2855-4. Epub 2014 Feb 12.

PMID:
24519386
10.

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.

Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N.

Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4. Epub 2013 Dec 11. Erratum in: Lancet Oncol. 2014 Feb;15(2):e52-3.

PMID:
24332514
11.

QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.

Nelson A, Fenlon D, Morris J, Sampson C, Harrop E, Murray N, Wheatley D, Hood K, Griffiths G, Barrett-Lee P.

Trials. 2013 Oct 9;14:325. doi: 10.1186/1745-6215-14-325.

12.

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA; NKTR-102 Study Group..

Lancet Oncol. 2013 Nov;14(12):1216-25. doi: 10.1016/S1470-2045(13)70429-7. Epub 2013 Oct 4.

PMID:
24095299
13.

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR; START Trialists' Group..

Lancet Oncol. 2013 Oct;14(11):1086-94. doi: 10.1016/S1470-2045(13)70386-3. Epub 2013 Sep 19.

PMID:
24055415
14.

γδ T cells predict outcome in zoledronate-treated breast cancer patients.

Welton JL, Martí S, Mahdi MH, Boobier C, Barrett-Lee PJ, Eberl M.

Oncologist. 2013;18(8):e22-3. doi: 10.1634/theoncologist.2013-0097. No abstract available.

15.

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group..

Lancet Oncol. 2013 Sep;14(10):962-70. doi: 10.1016/S1470-2045(13)70383-8. Epub 2013 Aug 19.

PMID:
23965225
16.

Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.

Lazaro G, Smith C, Goddard L, Jordan N, McClelland R, Barrett-Lee P, Nicholson RI, Hiscox S.

Endocr Relat Cancer. 2013 Aug 28;20(5):691-704. doi: 10.1530/ERC-13-0019. Print 2013 Oct.

17.

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.

Bartlett JM, A'hern R, Piper T, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Bliss JM, Ellis P, Barrett-Lee PJ.

Breast Cancer Res Treat. 2013 Apr;138(3):773-81. doi: 10.1007/s10549-013-2489-y. Epub 2013 Mar 28.

PMID:
23535839
18.

Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study.

Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, Boyages J, Christiansen P, Lee M, Wärnberg F, Allemani C, Engholm G, Fornander T, Gjerstorff ML, Johannesen TB, Lawrence G, McGahan CE, Middleton R, Steward J, Tracey E, Turner D, Richards MA, Coleman MP; ICBP Module 1 Working Group..

Br J Cancer. 2013 Mar 19;108(5):1195-208. doi: 10.1038/bjc.2013.6. Epub 2013 Feb 28.

19.

Pro-metastatic tumor-stroma interactions in breast cancer.

Gangadhara S, Barrett-Lee P, Nicholson RI, Hiscox S.

Future Oncol. 2012 Nov;8(11):1427-42. doi: 10.2217/fon.12.134. Review.

PMID:
23148616
20.

A prognostic tool to predict fatigue in women with early-stage breast cancer undergoing radiotherapy.

Courtier N, Gambling T, Enright S, Barrett-Lee P, Abraham J, Mason MD.

Breast. 2013 Aug;22(4):504-9. doi: 10.1016/j.breast.2012.10.002. Epub 2012 Oct 26.

PMID:
23103133

Supplemental Content

Loading ...
Support Center